Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
Clinical trial NCT07775287 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07775287
- Sponsor
- Genmab
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-15
- Primary completion
- 2029-03-30
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.